FI116270B - Förfarande för framställning av en stabiliserad formulering av prostaglandin E1 - Google Patents

Förfarande för framställning av en stabiliserad formulering av prostaglandin E1 Download PDF

Info

Publication number
FI116270B
FI116270B FI961797A FI961797A FI116270B FI 116270 B FI116270 B FI 116270B FI 961797 A FI961797 A FI 961797A FI 961797 A FI961797 A FI 961797A FI 116270 B FI116270 B FI 116270B
Authority
FI
Finland
Prior art keywords
pge
formulation
lactose
butyl alcohol
tertiary butyl
Prior art date
Application number
FI961797A
Other languages
English (en)
Finnish (fi)
Other versions
FI961797A0 (sv
FI961797A (sv
Inventor
Dirk L Teagarden
William J Petre
Paul M Gold
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FI961797A0 publication Critical patent/FI961797A0/sv
Publication of FI961797A publication Critical patent/FI961797A/sv
Application granted granted Critical
Publication of FI116270B publication Critical patent/FI116270B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI961797A 1993-10-27 1996-04-26 Förfarande för framställning av en stabiliserad formulering av prostaglandin E1 FI116270B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14369593A 1993-10-27 1993-10-27
US14369593 1993-10-27
PCT/US1994/009648 WO1995011683A1 (en) 1993-10-27 1994-09-06 Stabilized prostaglandin e¿1?
US9409648 1994-09-06

Publications (3)

Publication Number Publication Date
FI961797A0 FI961797A0 (sv) 1996-04-26
FI961797A FI961797A (sv) 1996-04-26
FI116270B true FI116270B (sv) 2005-10-31

Family

ID=22505188

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961797A FI116270B (sv) 1993-10-27 1996-04-26 Förfarande för framställning av en stabiliserad formulering av prostaglandin E1

Country Status (16)

Country Link
US (2) US5741523A (sv)
EP (1) EP0725642B1 (sv)
JP (1) JP3999263B2 (sv)
KR (1) KR100335549B1 (sv)
CN (1) CN1060042C (sv)
AT (1) ATE187071T1 (sv)
AU (1) AU688792B2 (sv)
DE (1) DE69421936T2 (sv)
DK (1) DK0725642T3 (sv)
ES (1) ES2142409T3 (sv)
FI (1) FI116270B (sv)
GR (1) GR3032817T3 (sv)
NO (1) NO309126B1 (sv)
NZ (1) NZ273752A (sv)
PT (1) PT725642E (sv)
WO (1) WO1995011683A1 (sv)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
KR100195348B1 (ko) * 1996-10-31 1999-06-15 장용택 안정한 프로스타글란딘 e1-함유 주사제 조성물
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
CA2295595A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
ES2253877T3 (es) * 1998-03-03 2006-06-01 SHIONOGI & CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6264981B1 (en) † 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
WO2005041897A2 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
TW200621240A (en) * 2004-11-05 2006-07-01 Salmedix Inc Cancer treatments
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
JPWO2006075690A1 (ja) * 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US20100222785A1 (en) * 2007-08-03 2010-09-02 Vanderbilt University Anchor driver
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
UA109109C2 (uk) * 2009-01-15 2015-07-27 Сефалон, Інк. Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
RS55491B2 (sr) 2010-01-28 2020-11-30 Eagle Pharmaceuticals Inc Formulacije bendamustina
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
AT518009A1 (de) * 2015-07-27 2017-06-15 Gebro Holding Gmbh Konzentrat enthaltend Alprostadil
CN109394704B (zh) * 2018-11-27 2021-09-17 西安力邦肇新生物科技有限公司 一种前列腺素e1甲酯注射用冻干制剂及制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3952004A (en) * 1974-06-18 1976-04-20 Pfizer Inc. Stabilized E-series prostaglandins
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
AU617678B2 (en) * 1987-05-22 1991-12-05 Liposome Company, Inc., The Prostaglandin-lipid formulations

Also Published As

Publication number Publication date
FI961797A0 (sv) 1996-04-26
KR100335549B1 (ko) 2002-11-29
US5741523A (en) 1998-04-21
AU7716794A (en) 1995-05-22
NO309126B1 (no) 2000-12-18
ES2142409T3 (es) 2000-04-16
EP0725642A1 (en) 1996-08-14
NO961718L (no) 1996-04-29
JP3999263B2 (ja) 2007-10-31
GR3032817T3 (en) 2000-06-30
NZ273752A (en) 1998-03-25
DE69421936D1 (de) 2000-01-05
DK0725642T3 (da) 2000-05-29
EP0725642B1 (en) 1999-12-01
CN1060042C (zh) 2001-01-03
CN1133561A (zh) 1996-10-16
AU688792B2 (en) 1998-03-19
NO961718D0 (no) 1996-04-29
US5770230A (en) 1998-06-23
KR960705572A (ko) 1996-11-08
PT725642E (pt) 2000-05-31
WO1995011683A1 (en) 1995-05-04
ATE187071T1 (de) 1999-12-15
FI961797A (sv) 1996-04-26
DE69421936T2 (de) 2000-06-29
JPH09504529A (ja) 1997-05-06

Similar Documents

Publication Publication Date Title
FI116270B (sv) Förfarande för framställning av en stabiliserad formulering av prostaglandin E1
AU2005304252B2 (en) Stabilized freeze-dried formulation for cephalosporin derivatives
KR20190086662A (ko) 카르글룸산을 함유하는 약제학적 비경구 제형
ES2215183T3 (es) Disoluciones inyectables o de infusion de enrofloxacino.
JPH03193735A (ja) グリコペプチド系抗生物質の安定化組成物
FI83476B (fi) Foerfarande foer framstaellning av en beredning av 7 -difluorometyltioacetamido-7 -metoxi-3-/1-(2 -hydroxialkyl)-1h-tetrazol-5-yl/tiometyl-1-detia-1-oxa-3-cefem-4 -karboxisyra.
EP1007094B1 (en) Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying
EP0251657B1 (en) Therapeutic compositions with galactitol as carrier
US6166062A (en) Pharmaceutical compositions containing phospholipase inhibitor
SK280840B6 (sk) Lyofilizovaný prípravok obsahujúci 1,1',1''-fosfinotioylidíntrisaziridín a spôsob jeho výroby
CN111346061B (zh) 绿原酸组合物及其制备方法
US5972912A (en) Method for lyophilizing ifosfamide
JP2022185009A (ja) 安定したアザシチジン含有医薬組成物の製造方法
WO2008026556A1 (fr) Préparation lyophilisée de 1-méthylcarbapenem
KR101314500B1 (ko) 안정성이 개선된 옥사세펨 제제 및 그 제조방법
KR20210144810A (ko) 벤조아제핀 화합물-함유 동결건조 조성물
RU2007152C1 (ru) Офтальмологическое средство и способ его получения
KR20230157353A (ko) 안정한 ruc-4 제형
SU1213973A3 (ru) Способ стабилизации антибактериальной щелочнометаллической соли 7В-(а-карбокси-а-арилацетамидо)-7 @ -метоксил-3-гетероциклотиометил-1-детиа-1-окса-3-цефем-4-карбоновой кислоты
MXPA00008596A (en) Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1, 2-dioxoethyl)- 2-ethyl-1-phenylmethyl) -1h-indol-4-yl]oxy]acetate
CZ20003208A3 (cs) Farmaceutické přípravky obsahující inhibitor fosfolipázy [[3-(2-amino-l,2-dioxoethyl)-2-ethyll-(fenylmethyl)-lH-indol-4-yl]oxy]acetát sodný

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: PHARMACIA & UPJOHN COMPANY

FG Patent granted

Ref document number: 116270

Country of ref document: FI